INTERNATIONAL PATENT: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH), EXIMMIUM BIOTECHNOLOGIES GMBH, KLINIKUM DER UNIVERSITAT MUNCHEN (LMU KLINIKUM) FILES APPLICATION FOR "COMPOSITION COMPRISING AN ANTIBODY WHICH BINDS TO HUMAN IGF2BP1 PRESENT ON THE CELL SURFACE OF A TARGET CELL"

GENEVA, June 23 -- HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (Ingolstadter LandstraBe 185764 Neuherberg), EXIMMIUM BIOTECHNOLOGIES GMBH (Feodor-Lynen-StraBe 2181377 Munchen), KLINIKUM DER UNIVERSITAT MUNCHEN (LMU KLINIKUM) (MarchioninistraBe 1581377 Munchen) filed a patent application (PCT/EP2024/086192) for "COMPOSITION COMPRISING AN ANTIBODY WHICH BINDS TO HUMAN IGF2BP1 PRESENT ON THE CELL SURFACE OF A TARGET CELL" on Dec 13, 2024. With publication no. WO/2025/125557, the details related to the patent application was published on Jun 19, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual P...